You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 53 No. 2, February 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Double-blind Study of Subcutaneous Dihydroergotamine vs Subcutaneous Sumatriptan in the Treatment of Acute Migraine

Paul Winner, DO; Orlando Ricalde, MD; Bruce Le Force, MD; Joel Saper, MD; Betty Margul, MD

Arch Neurol. 1996;53(2):180-184.


Abstract

Objective
To assess the efficacy and tolerability of subcutaneous dihydroergotamine mesylate (DHE-45) vs subcutaneous sumatriptan succinate (Imitrex) for the treatment of acute migraine with or without aura.

Design
Double-blind, randomized trial with parallel treatment arms.

Setting
Clinics and private neurology practices.

Subjects
Patients of either sex, with migraine with or without aura, between the ages of 18 and 65 years.

Interventions
Patients with moderate or severe head pain were randomized to receive either 1 mg of subcutaneous dihydroergotamine mesylate or 6 mg of subcutaneous sumatriptan succinate. Patients rated head pain, functional ability, nausea, and vomiting at baseline and at 0.5, 1, 2,4, and 24 hours after the injection. Presence or absence of headache at 3 hours was calculated from collected data. If pain persisted after 2 hours, a second injection of the same study medication was allowed, and self-ratings were repeated 30 and 60 minutes later. Follow-up data were collected at 24 hours.

Main Outcome Measures
Relief of head pain and recurrence of successfully treated headache.

Results
There were 295 evaluable patients. At 2 hours, 73.1% of the patients treated with dihydroergotamine and 85.3% of those treated with sumatriptan had relief (P=.002). There was no statistical difference in headache relief between the groups at 3 or 4 hours. Headache relief was achieved by 85.5% of those treated with dihydroergotamine and by 83.3% of those treated with sumatriptan by 4 hours. By 24 hours 89.7% of dihydroergotamine-treated patients and 76.7% of sumatriptan-treated patients had relief (P=.004). Headache recurred within 24 hours after treatment in 45% of the sumatriptan-treated patients and in 17.7% of the dihydroergotamine-treated patients (P≤.001).

Conclusions
Both sumatriptan and dihydroergotamine were effective in aborting migraine headaches. Headache recurrence was two and a half times as likely with sumatriptan as with dihydroergotamine.



Author Affiliations

From the Palm Beach Headache Center, West Palm Beach, Fla (Dr Winner), the Departments of Neurology, Keesler Medical Center, Keesler Air Force Base, Miss (Dr Ricalde), and Lackland Medical Center, Lackland Air Force Base, Tex (Dr Le Force), the Michigan Head Pain and Neurological Institute, Ann Arbor (Dr Saper), and Sandoz Pharmaceuticals, East Hanover, NJ (Dr Margul). Dr Le Force is now in private practice, San Antonio, Tex, and Dr Ricalde is at the Department of Neurology, Tulane University Medical School, New Orleans, La. For a list of the other participants in the study, see box on page 184.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

History of the Use of Ergotamine and Dihydroergotamine in Migraine From 1906 and Onward
Tfelt-Hansen and Koehler
Cephalalgia 2008;28:877-886.
ABSTRACT | FULL TEXT  

Tactile-Induced Ultrasonic Vocalization in the Rat: A Novel Assay to Assess Anti-Migraine Therapies in vivo
Martino and Perkins
Cephalalgia 2008;28:723-733.
ABSTRACT | FULL TEXT  

Randomized trial of IV dexamethasone for acute migraine in the emergency department
Friedman et al.
Neurology 2007;69:2038-2044.
ABSTRACT | FULL TEXT  

Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life
Lipton et al.
Neurology 2005;65:S50-S58.
ABSTRACT | FULL TEXT  

A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines
Friedman et al.
Neurology 2005;64:463-468.
ABSTRACT | FULL TEXT  

Migraine: pharmacotherapy in the emergency department
Kelly
Emerg. Med. J. 2000;17:241-245.
ABSTRACT | FULL TEXT  

Use and Overuse of Sumatriptan. Pharmacoepidemiological Studies Based on Prescription Register and Interview Data
Gaist
Cephalalgia 1999;19:735-761.
 

A triptan too far?
GOADSBY
J. Neurol. Neurosurg. Psychiatry 1998;64:143-147.
FULL TEXT  

Subcutaneous Dihydroergotamine vs Subcutaneous Sumatriptan
Catarci and Cerbo
Arch Neurol 1996;53:1215-1215.
ABSTRACT  

Subcutaneous Dihydroergotamine vs Subcutaneous Sumatriptan-Reply
Winner and Saper
Arch Neurol 1996;53:1215-1216.
ABSTRACT  

SUMATRIPTAN VS. DIHYDROERGOTAMINE FOR MIGRAINE
JWatch General 1996;1996:6-6.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.